IP Library Granted Patent US 11,331,282
Granted Patent B2
US 11,331,282 · App. 16/625,053 · Granted May 17, 2022

Ophthalmic composition containing clathrated antioxidant substance, and use thereof

Inventors: Junwen Qin (Tokyo, JP); Yuji Takahashi (Osaka, JP); Shigeru Kakuta (Tokyo, JP); Shigeru Kyuwa (Tokyo, JP)
A61K31/122A61K9/0048A61K9/08A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,331,282
App. No.
16/625,053
Granted
May 17, 2022
Kind
B2
Abstract

The present invention provides an ophthalmic composition and a use thereof. In one embodiment of the present invention, an ophthalmic composition containing a clathrated antioxidant substance is provided. In some of embodiments of the present invention, a composition for treating or preventing an ophthalmic disease, an ophthalmic disorder or an ophthalmic symptom is provided, wherein the ophthalmic disease, the ophthalmic disorder or the ophthalmic symptom includes, but is not limited to, dry eye or a dry eye-like ophthalmic disease, conjunctivitis, corneal ulcer, age-related macular degeneration, cataract, pseudoexfoliation syndrome, and symptoms in these diseases which can be ameliorated by increasing the quantity of tears and/or goblet cells and/or mucin.

Claims (7)

1. A method for treating or preventing an ophthalmic disease, ophthalmic disorder, or ophthalmic symptom in a subject, comprising administering an effective amount of astaxanthin clathrated with cyclodextrin to the subject.

2. The method of claim 1 , wherein

the cyclodextrin is α-cyclodextrin.

3. The method of claim 1 , wherein

a molar ratio of the astaxanthin and the cyclodextrin by mass is 2:1.

4. The method of claim 1 , wherein

the ophthalmic composition further includes sodium chloride, sodium dihydrogenphosphate dihydrate, benzalkonium chloride and sodium hydroxide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2019
From: QIN, JUNWEN; TAKAHASHI, YUJI; KAKUTA, SHIGERU; KYUWA, SHIGERU
To: TK HEALTH RESEARCH, CO. LTD.; THE UNIVERSITY OF TOKYO
Reel/Frame 051345/0648 →
Priority Claims (1)
JP JP2017-123224 · Jun 23, 2017 · national
Continuity (1)
Related Publication 20200138742A1 · May 7, 2020